1802998-75-9O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)OBFENHEAPFWQJFL-BTJKTKAUSA-NFilgotinib Maleate is the maleate form of filgotinib, an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.
1802998-75-9CHEMBL4298167安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]
P203, P260, P280, P318, P319, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
説明Filgotinib Maleate, the maleate form of filgotinib, is an oral bioactive inhibitor of the tyrosine kinase Janus kinase 1 (JAK1) with potential anti-inflammatory and immunomodulatory activities. JAK1 is a key enzyme in cytokine and growth factor-mediated signaling pathways for inflammation and immune function. Therefore, inhibiting the activity of JAK1 helps to exert therapeutic effects in various autoimmune diseases, inflammatory diseases, and certain malignant tumors.
現在のフィルター条件では反応記録がありません。
読み込み中…